Department of Psychiatry and Psycotherapy University of Cologne
Cologne, North Rhine-Westphalia, 50924, Germany
NCT Number: NCT00204061
The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used. An intensified clinical management (CM), which allows needs-based psychological crisis intervention, is compared to a combination of such a CM and the atypical neuroleptic amisulpride. The central hypothesis is that the combination of a clinical management with an atypical neuroleptic is the superior treatment.
Looking for future studies?
Notify Me14 year–36 year
All sexes
Interventional
Phase 4
Cologne, North Rhine-Westphalia, 50924, Germany
The first diagnosis of schizophrenia is preceded by a long lasting period comprising an untreated psychotic and a prodromal state. The duration of untreated psychosis correlates with a significant worsening of several outcome variables and persons fulfilling criteria of a prodromal state are already suffering from prodromal symptoms and from a significant deterioration of social and vocational functioning. However, a sufficient strategy for early intervention is still lacking. The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used. An intensified clinical management (CM), which allows needs-based psychological crisis intervention, is compared to a combination of such a CM and the atypical neuroleptic amisulpride. For analysis 130 patients will be recruited within three years, the treatment period is two years.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
AND / OR
Exclusion criteria
The needs-focused intervention could include psychoeducation, crisis intervention, family counselling and assistance with education or work-related difficulties, according to need. Regular psychotherapy was not permitted.
Other names: Clinical Management
Daily doses could range from 50 to 800 mg, with increments of 50 mg at first step and 100 mg at further steps. As a guideline, it was suggested that the dosage be increased as long as attenuated or brief limited intermittent positive symptoms were present. The interval between such steps should be at least 14 days if brief limited symptoms were absent and the APS score had improved.
Other names: Solian
Time frame: 3, 6, 12, 24 months
Decrease of symptom scores; complete remission of risk related symptoms
Time frame: 3, 6, 12, 24 months
Increase of Global Assessment of Functioning (GAF) scores
University of Cologne
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00159120
Mental Disorders, Psychoses
Düsseldorf, North Rhine-Westphalia, Germany
View Trial DetailsNCT00159133
Mental Disorders, Psychoses
Düsseldorf, North Rhine-Westphalia, Germany
View Trial DetailsNCT05808244
Mental Disorders, Psychosis
Kowloon, Hong Kong
View Trial DetailsNCT01945333
Mental Disorders, Psychotic Disorders
Brooklyn, New York, United States
View Trial Details